medicines transparency in jordan

16
Dr Taher Abu ElSamen Secretary General High Health Council MeTA in JORDAN MeTA 06/07/22 1

Upload: metapresents

Post on 27-Jan-2015

114 views

Category:

Health & Medicine


0 download

DESCRIPTION

Presentation on medicines transparency in Jordan at the launch of the Medicines Transparency Alliance (MeTA) in London, May 2008

TRANSCRIPT

Page 1: Medicines Transparency in Jordan

Dr Taher Abu ElSamenSecretary General

High Health Council

MeTA in JORDAN

MeTA 04/10/23 1

Page 2: Medicines Transparency in Jordan

04/10/23MeTA 2

Reasons for Jordan to be a MeTA pilot country

1. All regulations relating to registration & pricing of medicines & registered medicines prices on website

2. Transparent laws, regulations and procurement prices on website3. HAI/WHO medicine price survey conducted in 2004 and workshop

held in 2007 to recommend policy changes4. Commitment to form a comprehensive national Health Insurance

scheme (access, quality, equity)5. Aim to be a model in the region- share learning & collaboration in

medicines policies and regulations

Page 3: Medicines Transparency in Jordan

JORDAN

04/10/23MeTA 3

• GDP per capita: $2,500 US

• Health expenditure 10.4 % of GDP (30% of this spent on medicines)

• Total Medicine Expenditure $ 338 Million

• Public Medicine Expenditure $ 112.6 Million

• 25% Medicine expenditure public sector 75% in the private sector.

• No.of local medicines manufacturers: 16

• Medicines expenditure growth 17% per annum compared to GDP growth of 3.3%.

Page 4: Medicines Transparency in Jordan

Transparency 1. JFDA- all regulations relating to registration & pricing of

medicines & registered medicines prices on website2. JPD- transparent laws, regulations and procurement

prices on website3. RDU- reviewing NFD and creation of RDL4. High Health Council tasked to form a comprehensive

national Health Insurance scheme5. MoH Supplies Dept. has recently created its website. It

will contain information (availability, prices, shelf life, distribution) on all medicines & medical devices procured

Page 5: Medicines Transparency in Jordan

Accountability

In the past, lack of clear accountability Weak Civil Society National Agenda recently approved by the Royal Court & Prime

Ministry and emphasizes:- QUALITY at all levels of the health service- EQUITY in access to healthcare & medicines for whole population- All citizens must be covered by an appropriate HEALTH

INSURANCE- Performance budgeting- Key performance indicators- Encourages cooperation with national & int. Civil Society (CSOs)

Plan and need to IMPLEMENT, MONITOR and REVIEW !!

Page 6: Medicines Transparency in Jordan

04/10/23 6

MeTA Structures in JORDAN Formal agreement to pilot MeTA on 8 May 2008 includes: ( country launch planned for mid 2008)

Formation National multi-stakeholder MeTA Council- policy body- with membership of:

- PUBLIC: MoH, RMS, JFDA, JPD, HI, ( MoF, MOPIC)- PRIVATE: Local manufacturers, multinationals & agents, Health Insurance- CSO: National Consumer Society, International CSO

(HAI), Pharmacy and Medical Associations- Academics (pharmaco-economist)

MeTA Secretariat - coordinating role under MoH or HHC Ministry of Planning (MOPIC)- facilitator of project

Page 7: Medicines Transparency in Jordan

Status of MeTA workplan

Several areas of work identified by ALL stakeholders

Will be prioritised by MeTA Council to 3-4 areas for Phase I

Plan for an initial 6 months work plan followed by an 18 months workplan ( Phase I MeTA = 24 months)

Page 8: Medicines Transparency in Jordan

Main areas of work for MeTA (I)

Suggested areas of work identified by stakeholders to be prioritised to 3-4 by MeTA Council:

1. Revisit and analyse existing studies and data on medicines- identify gaps to conduct needed studies

2. Build capacity to collect data relating to medicines (eg procurement, prices, utilisation, expenditure etc.) to inform policy development and implementation

3. Build capacity of civil society (Health Action International has already started)

4. Identify best way to IMPLEMENT guidelines for the ethical promotion of medicines & MONITOR(JFDA has recently developed guidelines for the ethical promotion of medicines)

Page 9: Medicines Transparency in Jordan

Main areas of work for MeTA (II)5. Use medical evidence as the main criteria for the removal

and addition of medicines to the RDL. Develop an improved mechanism for monitoring the effectiveness of medicines using transparent measurement criteria

6. Disseminate information to both prescribers and patients on the quality of generics

7. Improve rational use of medicines, led by the newly formed RDU Dept. at the JFDA - include consolidation and implementation of Standard Treatment Guidelines and work with physicians to improve prescribing behaviour (e.g through continuing medical education programmes)

Page 10: Medicines Transparency in Jordan

National research needs Utilisation of medicines data Accurate data on expenditure on pharmaceuticals Measuring & monitoring of medicines availability & prices

( + price components) Actuarial studies for expanding health insurance system Perception of generics by prescribers and patients Quantifying risk groups (poor, elderly, chronic diseases) out

of pocket expenditures on medicines Measuring impact of Intellectual Property Rights (IPR) on

access to medicines

Page 11: Medicines Transparency in Jordan

Lessons learned so far…

Where there is a will there is a way to effect change!!

Better understanding of ALL stakeholders policy and operations regarding the medicines supply chain

There are some common issues/challenges that the three sectors (public, private and civil society) could share information and collaborate on

Page 12: Medicines Transparency in Jordan

Challenges, risks Assuring commitment & engagement of all stakeholders High medicine prices in private sector, low availability in public

sector Clarity and understanding of MeTA’s objectives to Jordan’s

MeTA Council stakeholders at ALL levels of their organisations Lack of good quality information and data Civil Society are in early stages of development Resistance to change How to make the MeTA approach SUSTAINABLE

Page 13: Medicines Transparency in Jordan

Support needs?

National & International Technical and financial assistance to conduct needed studies and research impacting on access to medicines

Capacity building for National information & planning systems relating to medicines

Capacity building for Civil Society Awareness campaign regarding MeTA objectives

and activities

Page 14: Medicines Transparency in Jordan

Other important messages?

Important not to forget that MeTA is a GLOBAL Alliance

- need for continuous communication & shared learning between & across MeTA pilot countries and also with International Secretariat to achieve the ultimate goal of improved access to medicines

Page 15: Medicines Transparency in Jordan

Questions from JORDAN to MeTA

Need for clarity on sources/mechanisms of technical and financial support

Is MeTA International committed with us for the long term????

Page 16: Medicines Transparency in Jordan

04/10/23 16

Thank you! Dr Taher Abu El Samen [email protected] Mobile Tel: +962797267444

National MeTA email / website (will be created) MeTA: www.MedicinesTransparency.org